- Humanigen (NASDAQ:HGEN) perks 7% premarket after executing its first licensing transaction in the Asia-Pacific Region with Telcon RF Pharmaceutical, Inc. and KPM Tech Co., Ltd for development and commercialization rights to lenzilumab for COVID-19 for South Korea and the Philippines.
- Telcon and KPM Tech, both recently invested in HGEN June 2020 PIPE offering.
- Agreement provides Humanigen up to $20M in milestones and double-digit royalties on product sales.
- Telcon and KPM Tech will be responsible for gaining regulatory approval and subsequent commercialization of lenzilumab in its territories.
- https://seekingalpha.com/news/3630295-humanigen-executes-lenzilumab-licensing-deal-in-asia-for-covidminus-19
Tuesday, November 3, 2020
Humanigen executes lenzilumab licensing deal in Asia for COVID-19
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.